CMO Announces Distribution of Commercial Drugs from New England Facility
Lyophilization Services of New England announces inspection approvals that will allow its Bedford, NH facility to begin manufacturing commercial drugs for US distribution.
On June 9, 2015, Lyophilization Services of New England (LSNE), a contract manufacturer of lyophilization services, announced the successful completion of a Pre-Approval Inspection (PAI) and General GMP Inspection by FDA in April 2015. The company’s manufacturing site, located in Bedford, NH, may now begin to manufacture commercial drugs for distribution within the US. Plans for 2015 also include “expansion of QC analytical testing capabilities, ICH stability chambers, additional complex formulation capabilities, as well as adding increased manufacturing capacity.”
"The completion of this inspection is a critical milestone for LSNE as it is the first PAI for a sterile product at the 25 Commerce Road facility. This is also our second site to now be successfully inspected by the FDA to produce commercial products in the past few months. This demonstrates LSNE's commitment to meeting all applicable regulatory standards for the production of commercial medical devices, bulk intermediates, and sterile injectable drugs,” said Shawn Cain, COO of LSNE, in a press release.
Source: LSNE
PostEra Expands Pfizer Partnership with AI Lab and ADC Collaborations
January 8th 2025The AI Lab was launched almost exactly three years ago and has produced several programs so far, at least one of which achieved its first scientific stage gate 40% faster than the teams originally forecasted.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
